Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 45% Improvement Relative Risk Kerr et al. Ivermectin for COVID-19 Prophylaxis Is prophylaxis with ivermectin beneficial for COVID-19? PSM retrospective 104 patients in Brazil (July - December 2020) Lower mortality with ivermectin (p=0.046) Kerr et al., Research Gate, doi:10.13140/RG.2.2.26793.52327 Favors ivermectin Favors control
COVID-19 In-Hospital Mortality Rate is Reduced by Prophylactic Use of Ivermectin: Findings From a City-Wide, Prospective Observational Study Using Propensity Score Matching (PSM)
Kerr et al., Research Gate, doi:10.13140/RG.2.2.26793.52327 (Preprint)
Kerr et al., COVID-19 In-Hospital Mortality Rate is Reduced by Prophylactic Use of Ivermectin: Findings From a City-Wide,.., Research Gate, doi:10.13140/RG.2.2.26793.52327 (Preprint)
Dec 2021   Source   PDF  
  All Studies   Meta
PSM retrospective 378 hospitalized patients in Brazil, showing lower mortality for patients that were on ivermectin prophylaxis before admission (not taking into account the lower risk of being hospitalized shown in the related larger study). This study is excluded in meta analysis: patients in this study are a subset of those in a larger study; not taking into account the lower risk of hospitalization shown in the related larger study.
risk of death, 45.0% lower, RR 0.55, p = 0.046, treatment 12 of 52 (23.1%), control 22 of 52 (42.3%), NNT 5.2, adjusted per study, propensity score matching, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kerr et al., 31 Dec 2021, retrospective, propensity score matching, Brazil, preprint, 9 authors, study period July 2020 - December 2020, dosage 200μg/kg days 1, 2, 16, 17, 0.2mg/kg/day for 2 days every 15 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: See discussions, stats, and author profiles for this publication at: COVID-19 In-Hospital Mortality Rate is Reduced by Prophylactic Use of Ivermectin: Findings From a City-Wide, Prospective Observational Study Using Propensity Score Matching (PSM) Preprint · December 2021 DOI: 10.13140/RG.2.2.26793.52327 CITATION READS 1 5,363 9 authors, including: Lucy Kerr Fernando Baldi Instituto Kerr São Paulo State University 11 PUBLICATIONS 93 CITATIONS 426 PUBLICATIONS 4,608 CITATIONS SEE PROFILE SEE PROFILE Raysildo Barbosa Lôbo Juan Chamie Center for Genetic Engineering and Biotechnology Universidad EAFIT 183 PUBLICATIONS 1,179 CITATIONS 8 PUBLICATIONS 11 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: ESTUDO DA VARIABILIDADE GENÉTICA DO PERFIL DE ACIDOS GRAXOS DA CARNE DE BOVINOS DA RAÇA NELORE TERMINADOS EM CONFINAMENTO View project Análise genômica de bovinos da raça Nelore (Bos indicus) para características quantitativas e qualitativas de carcaça e carne View project All content following this page was uploaded by Cadegiani Flávio on 26 December 2021. The user has requested enhancement of the 1 COVID-19 In-Hospital Mortality Rate is Reduced by Prophylactic Use of 2 Ivermectin: Findings From a City-Wide, Prospective Observational Study Using 3 Propensity Score Matching (PSM) 4 5 6 Lucy Kerr, MD, ARDMS1, Fernando Baldi, PhD2, Raysildo Barbosa Lôbo, PhD3, 7 Washington Luiz Olivato Assagra4, Fernando Carlos Proença5, Jennifer A. Hibberd, DDS, 8 DPD, MRCDC6, Juan J Chamie-Quintero7, Pierre Kory, MD, MPA8, Flavio A. Cadegiani, 9 MD, MSc, PhD8,9* 10 11 12 13 14 15 16 17 18 19 20 21 1 Instituto Kerr de Ensino e Pesquisa, São Paulo, Brazil Department of Animal Sciences, State University of São Paulo, São Paulo, Brazil 3 Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. 4 Centro Técnico de Avaliação Genômica C.T.A.G, Ribeirão Preto, Brazil 5 Itajaí City Hall, Itajaí, Brazil 6 University of Toronto, Toronto, Canada 7 Data Analysis, Universidad EAFIT, Cambridge, USA 8 Front-Line Covid-19 Critical Care Alliance (FLCCC), USA 9 Corpometria Institute, Brasilia, Brazil 2 22 23 24 25 26 27 28 29 *Corresponding author: Flávio A. Cadegiani, MD, MSc, PhD Corpometria Institute SGAS 915 Centro Clínico Advance, Rooms 260/262/264, Brasília, DF, Brazil,, +55 61 981.395.395 30 31 Key-words: COVID-19, SARS-CoV-2, ivermectin, prophylaxis, prevention, 32 coronavirus 33 34 Acromyums: COPD = Chronic Obstructive Pulmonary Disease; CVD = cardiovascular 35 disease; MI = Myocardial infarction; T2D = Type 2 Diabetes 36 37 38 39 40 41 42 43 1 44 45 46 47 Abstract 48 vaccines, a medical-based citywide governmental program offered ivermectin 49 prophylaxis for COVID-19 (city of Itajaí, state of Santa Catarina, Southern Brazi). The 50 aim of the present study was to evaluate the impact of prophylactic ivermectin use in in- 51 hospital COVID-19 mortality rate. 52 Materials and methods: We analyzed data from hospitalized COVID-19 patients of a 53 major COVID-19 reference hospital during a city-wide program of ivermectin 54 prophylaxis for COVID-19 (Hospital Marieta Konder Bornhausen, Itajaí, Santa Catarina, 55 Brazil), between July and December 2020. We..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop